CDP-Choline (Citicoline) vs Vinpocetine

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

CDP-Choline (Citicoline)Vinpocetine
CategoryNootropicsNootropics
Standard Dose250-500 mg/day5-20 mg 2-3 times daily (15-60 mg/day total)
TimingMorning or split morning/afternoon. With or without food.With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycle DurationOngoing; no cycling requiredCycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Evidence Levelstrong_humanmoderate_human

Mechanism

Prodrug that is hydrolyzed to choline and cytidine upon oral ingestion. Choline supports acetylcholine synthesis and phosphatidylcholine membrane repair. Cytidine is converted to uridine, which enhances synaptic membrane synthesis via the Kennedy pathway and upregulates dopamine receptor density. This dual mechanism — cholinergic support plus dopaminergic modulation — is unique among choline sources.

Standard Dosing

250-500 mg/day

Timing

Morning or split morning/afternoon. With or without food.

Cycle Duration

Ongoing; no cycling required

Side Effects

  • GI distress
  • Headache
  • Insomnia (due to dopaminergic activity)
  • Diarrhea at high doses

Contraindications

  • Known hypersensitivity to citicoline

Best Stacking Partners

PiracetamAniracetamUridineDHALion's Mane
B

Vinpocetine

Nootropics

Mechanism

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Standard Dosing

5-20 mg 2-3 times daily (15-60 mg/day total)

Timing

With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Side Effects

  • Flushing
  • GI distress
  • Headache
  • Dizziness
  • Transient hypotension
  • Sleep disturbance

Contraindications

  • Severe hepatic impairment
  • Pregnancy and lactation (FDA issued warning in 2019)
  • Severe cardiac arrhythmias
  • Recent hemorrhagic stroke

Best Stacking Partners

Ginkgo BilobaAlpha-GPCPiracetamPhosphatidylserine

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →